Among BRCA1/2 carriers with advanced breast cancer, PARP inhibitors showed some activity even in patients with platinum resistant/unresponsive disease. However, the optimal delivery of platinum agents and PARP inhibitors was not clear.1 In another study of BRCA1/2 carriers with breast cancer (OlympiAD Trial), PARP inhibitors were compared to chemotherapy Treatment of Physician’s Choice (TPC), with 25.7 months follow up, and the following results were generated:2
| PARP | TPC | |
| Overall Survival | 18.9 months | 15.5 months |
| Alive at 3 Years | 40.8% | 12.8% |
Of note, the effect was greatest in those receiving Olaparib for first line treatment (22.6 months) compared to not first line (14.7 months). Furthermore, benefit was seen regardless of hormone receptor status, BRCA status (BRCA1 versus BRCA2), site of metastasis, amount of prior treatment, and stage of disease progression.3
1Valenza, et al. Eur J Cancer. 2023;190:112944. PMID: 37437366;
2Robson, et al. Eur J Cancer. 2023;184:39-47. PMID: 36893711;
3Senkus, et al. Int J Cancer. 2023;153(4):803-814. PMID: 36971103.